Crossmark

Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib

Crossref DOI link: https://doi.org/10.1007/s12020-014-0448-y

Published Online: 2014-10-11

Published Print: 2015-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Marotta, Vincenzo

Di Somma, Carolina

Rubino, Manila

Sciammarella, Concetta

Modica, Roberta

Camera, Luigi

Del Prete, Michela

Marciello, Francesca

Ramundo, Valeria

Circelli, Luisa

Buonomano, Pasqualina

Colao, Annamaria

Faggiano, Antongiulio
License Information

Text and Data Mining valid from 2014-10-11